Baxter International (BAX) Cash & Equivalents (2009 - 2026)

Baxter International (BAX) has reported Cash & Equivalents for 18 consecutive years, with $2.2 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 27.52% year-over-year to $2.2 billion; the TTM figure through Jun 2026 stood at $2.2 billion (up 27.52% YoY), while the FY2025 annual figure was $2.0 billion, up 11.68% from the prior year.
• Cash & Equivalents improved to $2.2 billion in Q2 2026 per BAX's latest filing, from $2.0 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $5.7 billion in Q3 2023 and bottomed at $1.4 billion in Q3 2024.
• Historically, Cash & Equivalents has averaged $2.2 billion across 5 years, with a median of $1.8 billion in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 257.03% — and 2024, when it tumbled 75.16%.
• Baxter International's Cash & Equivalents stood at $1.6 billion in 2022, then surged by 89.88% to $3.1 billion in 2023, then tumbled by 42.69% to $1.8 billion in 2024, then grew by 11.68% to $2.0 billion in 2025, then climbed by 9.14% to $2.2 billion in 2026.
• Business Quant data shows BAX's Cash & Equivalents at $2.2 billion in Q2 2026, $2.0 billion in Q1 2026, and $2.0 billion in Q4 2025.